ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Takeda Pharmaceutical will pay Carmine Therapeutics an undisclosed sum and up to $900 million in milestone payments as part of a deal to develop nonviral gene therapies for two rare diseases. Carmine was founded last year in Cambridge, Massachusetts, to pioneer a new class of gene therapies based on red blood cell extracellular vesicles (RBCEVs). Compared to adeno-associated virus-based gene therapy, RBCEV-based gene therapy has the potential for larger payloads and repeat dosing, Carmine says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X